SCHEMBL5603398

SCHEMBL5603398

O=C(Cc1ccc([N+](=O)[O-])cc1)NO

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.60
ALDH1A1 P00352 5/20 0.60
MEN1 O00255 4/20 0.60
MAPT P10636 2/20 0.60
HTT P42858 1/20 0.60
HDAC8 Q9BY41 2/20 0.56
HDAC3 O15379 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC2 Q92769 1/20 0.56
LMNA P02545 1/20 0.56
HDAC6 Q9UBN7 1/20 0.55
MMP1 P03956 1/20 0.55
MMP2 P08253 1/20 0.55
MMP9 P14780 1/20 0.55
MMP8 P22894 1/20 0.55
MMP13 P45452 1/20 0.55
CYP1A2 P05177 1/20 0.54
CYP2C19 P33261 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
GLA P06280 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2494960 0.84 KMT2A (0.59) KMT2AALDH1A1MEN1MAPTHTT
SCHEMBL990297 0.84 ALDH1A1 (0.60) KMT2AALDH1A1MEN1MAPTHTT
SCHEMBL5067751 0.81 ALDH1A1 (0.57) KMT2AALDH1A1MEN1MAPTHTT
SCHEMBL6932662 0.80 CYP2C19 (0.61) KMT2AALDH1A1MEN1MAPTHTT
SCHEMBL4833805 0.80 IDO1 (0.51) KMT2AALDH1A1MEN1MAPTHTT
SCHEMBL2510372 0.80 KMT2A (0.56) KMT2AALDH1A1MEN1MAPTHTT
SCHEMBL22570415 0.80 HDAC1 (0.66) KMT2AALDH1A1MEN1HDAC8HDAC3
SCHEMBL5184989 0.79 ALDH1A1 (0.69) KMT2AALDH1A1MEN1MAPTHTT
SCHEMBL1369962 0.79 CYP2C19 (0.59) KMT2AALDH1A1MEN1MAPTHTT
SCHEMBL76204 0.79 CYP2C19 (0.64) KMT2AALDH1A1MEN1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100360580-C Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds AVENTIS PHARM PROD INC (US) 2008-01-09 CN disclosed
EP-0946478-B1 PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES AND HYDROXAMIC ACID COMPOUNDS AVENTIS PHARMA INC (US) 2007-02-14 EP disclosed
EP-1688406-A2 Polymeric resin compounds and their preparation Aventis Pharmaceuticals Products Inc. (US) 2006-08-09 EP disclosed
EP-1674484-A2 Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid componds Aventis Pharmaceuticals Products Inc. (US) 2006-06-28 EP disclosed
CN-1769318-A Polymeric resin compounds and their preparation AVENTIS PHARM PROD INC (US) 2006-05-10 CN disclosed
CN-1754899-A Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds AVENTIS PHARM PROD INC (US) 2006-04-05 CN disclosed
CN-1238323-C Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds AVENTIS PHARMA INC (US) 2006-01-25 CN disclosed
CN-1235925-C Solid phase synthesing method of aldehyde, ketonic, oxime amine and isohydroximic acid compound AVENTIS MEDICINE CORP (US) 2006-01-11 CN disclosed
EP-0946478-A4 PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS AVENTIS PHARM PROD INC (US) 2004-09-08 EP disclosed
CN-1500769-A Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds ���µ�˹ҩ�﹫˾ 2004-06-02 CN disclosed
EP-1089958-A2 PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND ALPHA,BETA-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS Aventis Pharmaceuticals Products Inc. (US) 2001-04-11 EP disclosed
US-6133409-A REACTING A SOLID SUPPORT-BOUND N-ALKYLATED HYDROXAMIC ACID WITH A CARBON-NITROGEN CLEAVING ORGANOMETALLIC COMPUND TO LIBERATE THE PRODUCT KETONE AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-10-17 US disclosed
US-6057369-A USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 2000-05-02 US disclosed
CN-1240418-A Solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds RHONE POULENC RORER PHARMA (US) 2000-01-05 CN disclosed
WO-1999067192-A2 PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-12-29 WO disclosed
EP-0946478-A1 PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-10-06 EP disclosed
EP-0871439-A4 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE POULENC RORER PHARMA (US) 1999-07-21 EP disclosed
EP-0871439-A1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1998-10-21 EP disclosed
WO-1998029376-A1 PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-07-09 WO disclosed
WO-1997024117-A1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-10 WO disclosed